ClinicalTrials.gg
Not yet recruitingNCT07145385CHAMADUpdated Jan 5, 2026

Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer

An observational study in Retrospective Cohort of Patients Diagnosed With HCC on Non-Cirrhotic Liver, sponsored by University Hospital, Bordeaux. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by University Hospital, Bordeaux · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
71
Ages
18 Years and older
Sex
All
01

Study summary

Patients with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease, have a 20- to 50-fold higher risk of developing primary liver cancer (PLC), such as hepatocellular carcinoma (HCC), in both cirrhotic and non-cirrhotic livers, highlighting AATD as a potential oncogenic factor. Therefore, our aim is to evaluate the association between AATD and HCC in patients with a non-cirrhotic liver and no known predisposition

Read the detailed description

The two most common pathogenic AATD variants, PiS and PiZ, will be identified using the multiplex digital PCR (dPCR) system in a French cohort of 71 patients who developed HCC in a non-cirrhotic liver without known risk factors for HCC

02

Conditions studied

  • Retrospective Cohort of Patients Diagnosed With HCC on Non-Cirrhotic Liver

Keywords

  • Prevalence
  • Alpha-1 Antitrypsin Deficiency
  • HCC on Non-Cirrhotic Liver
  • Retrospective Cohort
03

In context

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

This study's planned enrollment of 71 is below the median of 160 across 46 observational studies indexed under alpha 1-Antitrypsin Deficiency.

Browse alpha 1-Antitrypsin Deficiency studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients Diagnosed with HCC on non-cirrhotic liver

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (≥18 years of age).
  2. Histopathologically confirmed diagnosis of hepatocellular carcinoma (HCC).
  3. Normal liver or chronic liver disease with minimal to moderate fibrosis in non-tumoral tissue.
  4. Signed obtained prior to participation.
  5. No other known etiology or risk factors for liver disease, including:

    • Alcohol-related liver disease
    • Metabolic-associated steatohepatitis (MASH)
    • Viral hepatitis infections
    • Hemochromatosis

Exclusion criteria

Exclusion Criteria:

  1. Minor patients (\<18 years of age).
  2. HCC diagnosis not established according to standard histopathological criteria.
  3. Liver with chronic liver disease showing advanced fibrosis in non-tumoral tissue.
  4. No signed prior to participation.
  5. Presence of other identified etiologies or known risk factors for liver disease, including:

    • Alcohol-related liver disease
    • Metabolic-associated steatohepatitis (MASH)
    • Viral hepatitis infections
    • Hemochromatosi
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
71 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients Diagnosed with HCC on Non-Cirrhotic Liver

    Patients Diagnosed with HCC on Non-Cirrhotic Liver

    Other: multiplex digital PCR

Interventions

  • Othermultiplex digital PCR

    multiplex digital PCR

06

What researchers measure

Primary outcomes

  1. Prevalence of Alpha-1 Antitrypsin Deficiency

    Prevalence of Alpha-1 Antitrypsin Deficiency in a Retrospective Cohort of Patients Diagnosed with HCC on Non-Cirrhotic Liver up to 1 year

    Time frame: 1 year

Secondary outcomes

  1. Correlation of clinico-biological parameters-including survival (years), sex, BMI, fibrosis stage, mode of diagnosis, number of tumors, tumor size (mm), metastasis, recurrence, and Edmondson score-according to AAT genotype

    Correlation of clinico-biological parameters-including survival (years), sex, BMI, fibrosis stage, mode of diagnosis, number of tumors, tumor size (mm), metastasis, recurrence, and Edmondson score-according to AAT genotype. up to 1 year

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Beaufrere A, Leon C, Decreaker M, Possenti L, Evain M, Coilly A, Schneider CV, Feurer Z, Odou MF, Balduyck M, Payance A, Schneider KM, Bioulac P, Blanc JF, Le Bail B, Guettier C, Amintas S, Bouchecareilh M. Alpha-1 Antitrypsin Deficiency Alleles in Non-Cirrhotic Hepatocellular Carcinoma: Insights from a Multicenter French Cohort. J Clin Exp Hepatol. 2026 Jul-Aug;16(4):103545. doi: 10.1016/j.jceh.2026.103545. Epub 2026 Apr 3. PubMed 42064227 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Sep 2027, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Aug 28, 2025
StartEst.
Jan 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07145385
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Jan 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 5, 2026

Study contacts

Marie Decraecker, MD
Contact
marie.decraecker@chu-bordeaux.fr
+335 57 65 64 38

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion